CRPC with Bone Metastases COE

Decreased Fracture Rate When Adding Bone Protecting Agents to Radium-223: PEACE III- Bertrand F. Tombal Details Bertrand Tombal discusses the ongoing PEACE III trial evaluating enzalutamide alone versus enzalutamide plus radium-223 post the ERA-223 data. The interim safety analysis was presented at ASCO and the data demonstrated that there was an increase fracture rate with the addition of radium-223 to enzalutamide prior to mandating the use of bone protecting agents. Pathological and non-pathological frac...
Real World Treatment Experience with Radium-223 - Dan George Details Dan George concentrated on the patient experience in the treatment of metastatic castration-resistant prostate cancer (mCRPC). He described a typical treatment timeline where a new patient presents with elevated PSA is initially treated with androgen deprivation therapy (ADP) to reduce testosterone feeding tumor growth. While the patient may initially respond with a reduced PSA, it is most common...
Bone Health in Prostate Cancer - A Conversation with Neal Shore and Oliver Sartor Details Neal Shore and Oliver Sartor have a conversation on bone-targeted agent therapies in prostate cancer, specifically focusing on the ALSYMPCA phase three trial; the design, findings, the addition of radium-223 and what this trial has led to today. They review a few other current ongoing trials including the PEACE III single arm trial and other current approaches in understanding combination therapie...

Decreased Fracture Rate When Adding Bone Protecting Agents to Radium-223: PEACE III- Bertrand F. Tombal